{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:24:52Z","timestamp":1790774692988,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007555","name":"Foundation for Cardiovascular Research","doi-asserted-by":"publisher","award":["32003B-116382"],"award-info":[{"award-number":["32003B-116382"]}],"id":[{"id":"10.13039\/100007555","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Basel Cardiovascular Research Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The new generation thinner-strut silicon carbide (SiC) coated cobalt chromium (CoCr) bare-metal stents (BMS) are designed to accelerate rapid endothelialisation and reduce thrombogenicity when implanted in coronary arteries. However, smaller studies suggest higher rates of symptomatic restenosis in patients receiving the newer generation BMS.<\/jats:p>\n                <jats:p>We investigated the efficacy of a newer generation ultrathin strut silicon-carbide coated cobalt-chromium (CoCr) BMS (SCC-BMS) as compared to an older thin-strut uncoated CoCr BMS (UC-BMS) in patients presenting with coronary artery disease requiring stenting of large vessels (\u22653.0\u2009mm).<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>All patients randomized to SCC- (<jats:italic>n<\/jats:italic>\u2009=\u2009761) or UC-BMS (<jats:italic>n<\/jats:italic>\u2009=\u2009765) in the two BASKET-PROVE trials were included. Design, patients, interventions and follow-up were similar between trials except differing regimens of dual antiplatelet therapy. The primary endpoint was clinically driven target-vessel revascularization within 24\u2009months. Safety endpoints of cardiac death, non-fatal myocardial infarction (MI), and definite\/probable stent thrombosis (ST) were also assessed. We used inverse probability weighted proportional hazards Cox regressions adjusting for known confounders.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Demographics, clinical presentation, and risk factors were comparable between the groups, but patients receiving SCC-BMS underwent less complex procedures. The risk for clinically driven TVR was increased om the SCC-BMS group compared to the UC-BMS group (cumulative incidence, 10.6% vs. 8.4%; adjusted relative hazard [HR], 1.49 [95% CI, 1.05\u20132.10]). No differences in safety endpoints were detected, cardiac death (1.6% vs. 2.8%; HR, 0.62 [CI, 0.30\u20131.27]), non-fatal MI (3.2% vs. 2.5%; HR, 1.56 [CI, 0.83\u20132.91]), and definite\/probable ST (0.8% vs. 1.1%; HR, 1.17 [CI, 0.39\u20133.50]). Differences in strut thickness between the two stents did not explain the association between stent type and clinically driven TVR.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In patients requiring stenting of large coronary arteries, use of the newer generation SCC-BMS was associated with a higher risk of clinically driven repeat revascularization compared to the UC-BMS with no signs of an offsetting safety benefit.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-019-1199-8","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T15:10:13Z","timestamp":1571238613000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Do ultrathin strut bare-metal stents with passive coating improve efficacy in large coronary arteries? Insights from the randomized, multicenter BASKET-PROVE trials"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0851-5095","authenticated-orcid":false,"given":"Kim Wadt","family":"Hansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raban","family":"Jeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Pfisterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tor","family":"Biering-S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise Hougesen","family":"Bjerking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Galatius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,16]]},"reference":[{"key":"1199_CR1","doi-asserted-by":"crossref","unstructured":"Valgimigli M, Sabate M, Kaiser C, Brugaletta S, de la Torre Hernandez JM, Galatius S, et al. Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis. Bmj. 2014;349:g6427\u20137.","DOI":"10.1136\/bmj.g6427"},{"issue":"23","key":"1199_CR2","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1016\/j.jacc.2015.04.017","volume":"65","author":"T Palmerini","year":"2015","unstructured":"Palmerini T, Benedetto U, Biondi-Zoccai G, Della Riva D, Bacchi-Reggiani L, Smits PC, et al. Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2015;65(23):2496\u2013507.","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"1199_CR3","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1093\/eurheartj\/eht570","volume":"35","author":"S-H Kang","year":"2014","unstructured":"Kang S-H, Park KW, Kang D-Y, Lim W-H, Park KT, Han J-K, et al. Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis. Eur Heart J. 2014;35(17):1147\u201358.","journal-title":"Eur Heart J"},{"key":"1199_CR4","doi-asserted-by":"crossref","unstructured":"Wittchow E, Hartwig S. Still room for improvement: preclinical and bench testing of a thin-strut cobalt-chromium bare-metal stent with passive coating. J Biomed Mater Res - Part B Appl Biomater. 2016:1\u201310.","DOI":"10.1002\/jbm.b.33702"},{"issue":"4","key":"1199_CR5","doi-asserted-by":"publisher","first-page":"502","DOI":"10.4244\/EIJV4I4A85","volume":"4","author":"JB Dahm","year":"2009","unstructured":"Dahm JB, Willems T, Wolpers HG, Nordbeck H, Becker J, Ruppert J. Clinical investigation into the observation that silicon carbide coating on cobalt chromium stents leads to early differentiating functional endothelial layer, increased safety and DES-like recurrent stenosis rates: results of the PROHeal registry (PRO-kinetic enhancing rapid in-stent endothelialisation). EuroIntervention. 2009;4(4):502\u20138.","journal-title":"EuroIntervention."},{"issue":"8","key":"1199_CR6","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.carrev.2014.10.002","volume":"15","author":"R Erbel","year":"2014","unstructured":"Erbel R, Eggebrecht H, Roguin A, Schroeder E, Philipp S, Heitzer T, et al. Prospective, multi-center evaluation of a silicon carbide coated cobalt chromium bare metal stent for percutaneous coronary interventions: two-year results of the ENERGY registry. Cardiovasc Revascularization Med. 2014;15(8):381\u20137.","journal-title":"Cardiovasc Revascularization Med"},{"issue":"6","key":"1199_CR7","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/j.1540-8183.2011.00672.x","volume":"24","author":"M Abdel-Wahab","year":"2011","unstructured":"Abdel-Wahab M, Toelg R, Kassner G, Klatt L, Sherif MA, Geist V, et al. Long-term clinical outcome of thin-strut cobalt-chromium stents in the drug-eluting stent era: results of the COBALT (comparison of bare-metal stents in all-comers\u2019 lesion treatment) registry. J Interv Cardiol. 2011;24(6):496\u2013504.","journal-title":"J Interv Cardiol"},{"issue":"9","key":"1199_CR8","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.cjca.2012.11.030","volume":"29","author":"SE Haine","year":"2013","unstructured":"Haine SE, Cornez BM, Jacobs JM, Miljoen HP, Vandendriessche TR, Claeys MJ, et al. Difference in clinical target lesion revascularization between a silicon carbide-coated and an uncoated thin strut bare-metal stent: the PRO-vision study. Can J Cardiol. 2013;29(9):1090\u20136.","journal-title":"Can J Cardiol"},{"key":"1199_CR9","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.ahj.2007.11.011","volume":"155","author":"M Pfisterer","year":"2008","unstructured":"Pfisterer M, Bertel O, Bonetti PO, Brunner-La Rocca HP, Eberli FR, Erne P, et al. Drug-eluting or bare-metal stents for large coronary vessel stenting? The BASKET-PROVE (PROspective validation examination) trial: study protocol and design. Am Heart J. 2008;155:609\u201314.","journal-title":"Am Heart J"},{"issue":"24","key":"1199_CR10","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1056\/NEJMoa1009406","volume":"363","author":"C Kaiser","year":"2010","unstructured":"Kaiser C, Galatius S, Erne P, Eberli F, Alber H, Rickli H, et al. Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med. 2010;363(24):2310\u20139.","journal-title":"N Engl J Med"},{"issue":"2","key":"1199_CR11","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ahj.2011.08.023","volume":"163","author":"R Jeger","year":"2012","unstructured":"Jeger R, Pfisterer M, Alber H, Eberli F, Galatius S, Naber C, et al. Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: the BAsel stent Kosten Effektivit\u00e4ts trial PROspective validation examination part II (BASKET-PROVE II) trial design. Am Heart J. 2012;163(2):136\u201341.","journal-title":"Am Heart J"},{"issue":"1","key":"1199_CR12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1161\/CIRCULATIONAHA.114.013520","volume":"131","author":"C Kaiser","year":"2014","unstructured":"Kaiser C, Galatius S, Jeger R, Gilgen N, Jensen JS, Naber CK, et al. Long-term efficacy and safety of biodegradable-polymer Biolimus-eluting stents: Main results of the Basel stent Kosten-Effektivit\u00e4ts trial- PROspective validation examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome tri. Circulation. 2014;131(1):74\u201381.","journal-title":"Circulation."},{"issue":"17","key":"1199_CR13","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","volume":"115","author":"DE Cutlip","year":"2007","unstructured":"Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, Van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344\u201351.","journal-title":"Circulation."},{"issue":"6","key":"1199_CR14","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","volume":"18","author":"TA Gooley","year":"1999","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695\u2013706.","journal-title":"Stat Med"},{"issue":"10","key":"1199_CR15","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1097\/MLR.0b013e31806518ac","volume":"45","author":"LH Curtis","year":"2007","unstructured":"Curtis LH, Hammill BG, Eisenstein EL, Kramer JM, Anstrom KJ. Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care. 2007;45(10):S103\u20137.","journal-title":"Med Care"},{"issue":"387","key":"1199_CR16","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/01621459.1984.10478078","volume":"79","author":"PR Rosenbaum","year":"1984","unstructured":"Rosenbaum PR, Rubin DB. Reducing Bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984;79(387):516\u201324.","journal-title":"J Am Stat Assoc"},{"key":"1199_CR17","unstructured":"Team RDC. R: a language and environment for statistical computing. [internet]. Vol. 1, R Foundation for statistical computing. Vienna, Austria: (R Core team) R Foundation for statistical Computing; 2013."},{"issue":"6","key":"1199_CR18","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/ccd.27434","volume":"92","author":"TT Michael","year":"2018","unstructured":"Michael TT, Richardt G, Lansky A, Carney RJ, Khan MA, Shehadeh A, et al. Nine-month results of the BIOHELIX-I clinical trial study: evaluation of the PRO-kinetic Energy cobalt chromium bare-metal stent system. Catheter Cardiovasc Interv. 2018;92(6):1030\u20139.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"15","key":"1199_CR19","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.jacc.2018.02.023","volume":"71","author":"J Torrado","year":"2018","unstructured":"Torrado J, Buckley L, Dur\u00e1n A, Trujillo P, Toldo S, Valle Raleigh J, et al. Restenosis, stent thrombosis, and bleeding complications: navigating between Scylla and Charybdis. J Am Coll Cardiol. 2018;71(15):1676\u201395.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1199_CR20","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.ahj.2012.01.007","volume":"163","author":"H Kitabata","year":"2012","unstructured":"Kitabata H, Kubo T, Komukai K, Ishibashi K, Tanimoto T, Ino Y, et al. Effect of strut thickness on neointimal atherosclerotic change over an extended follow-up period (\u2265 4 years) after bare-metal stent implantation: intracoronary optical coherence tomography examination. Am Heart J. 2012;163(4):608\u201316.","journal-title":"Am Heart J"},{"issue":"3","key":"1199_CR21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0735-1097(02)01989-7","volume":"40","author":"C Briguori","year":"2002","unstructured":"Briguori C, Sarais C, Pagnotta P, Liistro F, Montorfano M, Chieffo A, et al. In-stent restenosis in small coronary arteries: impact of strut thickness. J Am Coll Cardiol. 2002;40(3):403\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1199_CR22","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S0735-1097(03)00119-0","volume":"41","author":"J Pache","year":"2003","unstructured":"Pache J, Kastrati A, Mehilli J, Sch\u00fchlen H, Dotzer F, Hausleiter J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol. 2003;41(8):1283\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"1199_CR23","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1161\/01.CIR.91.12.2995","volume":"91","author":"C Rogers","year":"1995","unstructured":"Rogers C, Edelman ER. Endovascular stent design dictates experimental restenosis and thrombosis. Circulation. 1995;91(12):2995\u20133001.","journal-title":"Circulation."},{"issue":"3","key":"1199_CR24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.addr.2006.01.022","volume":"58","author":"H Hara","year":"2006","unstructured":"Hara H, Nakamura M, Palmaz JC, Schwartz RS. Role of stent design and coatings on restenosis and thrombosis. Adv Drug Deliv Rev. 2006;58(3):377\u201386.","journal-title":"Adv Drug Deliv Rev"},{"issue":"10105","key":"1199_CR25","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/S0140-6736(17)32249-3","volume":"390","author":"DE Kandzari","year":"2017","unstructured":"Kandzari DE, Mauri L, Koolen JJ, Massaro JM, Doros G, Garcia-Garcia HM, et al. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. Lancet. 2017;390(10105):1843\u201352.","journal-title":"Lancet."},{"issue":"20","key":"1199_CR26","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus Clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001\u201315.","journal-title":"N Engl J Med"},{"issue":"12","key":"1199_CR27","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/S0735-1097(02)02597-4","volume":"40","author":"DE Cutlip","year":"2002","unstructured":"Cutlip DE, Chauhan MS, Baim DS, Ho KKL, Popma JJ, Carrozza JP, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol. 2002;40(12):2082\u20139.","journal-title":"J Am Coll Cardiol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-019-1199-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12872-019-1199-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-019-1199-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T23:16:58Z","timestamp":1602717418000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-019-1199-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,16]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1199"],"URL":"https:\/\/doi.org\/10.1186\/s12872-019-1199-8","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,16]]},"assertion":[{"value":"27 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocols of the BASKET-PROVE and BASKET-PROVE II trials complied with the declaration of Helsinki and was approved by the local ethics committee at each participating site. Written informed consent was been obtained from all patients. The following local ethics committees were consulted [reference number]:<i>The BASKET-PROVE trial:<\/i>Den Videnskabsetiske Komite | Regionsg\u00e5rden, Kongens V\u00e6nge 2, 3400 Hiller\u00f8d, Denmark [H-KA-20070005].Ethikkommission St. Gallen, Flurhof 7, 9007\u2009St. Gallen, Switzerland [EKSG 007\/027\/1B].SPUK f\u00fcr Stadtspital Triemli, Ethikkommission des Kantons Z\u00fcrich, Birmensdorfstrasse 497, 8063 Z\u00fcrich, Switzerland [SZT 17\/07].Kantonale Ethikkommission des Kantons Luzern, Kinderspital, 6000 Luzern, Switzerland [Antrag 671].Kantonale Ethikkommission Graub\u00fcnden, Hofgraben 5, 7001 Chur, Switzerland [14\/07].Ethikkommission beider Basel, Hebelstrasse 53, 4056 Basel, Switzerland [327\/06].Ethikkommission der Medizinischen Universit\u00e4t Innsbruck, Innrain 43, 6020 Innsbruck, Austria [AM3043a].Ethik-Kommission der Gesundheitsdirektion Z\u00fcrich (SPUK Innere Medizin), Sonneggstrasse 12, 8031 Z\u00fcrich, Switzerland [EK-1400].Comitato Etico Cantonale, Via Orico 5, 6501 Bellinzona, Switzerland [CE1872].Comitato Etico, Ospidale Civile di Legnano, Via Candiani 2, 20025 Legnano, Italy [Pratica nr. 524\/20074].<i>The BASKET-PROVE II trial:<\/i>Ethikkommission beider Basel EKBB, Hebelstrasse 53, 4056 Basel, Switzerland [231\/09].De Videnskabsetiske Komiteer i Region Hovedstaden, Kongens V\u00e6nge 2, 3400 Hiller\u00f8d, Denmark [H-1-20091101].Ethikkommission der Medizinischen Universit\u00e4t Innsbruck, Innrain 43, 6020 Innsbruck, Austria [264\/4.12].Ethikkommission der \u00c4rztekammer Nordrhein, Tersteegenstrasse 9, 40474 D\u00fcsseldorf, Germany [2010007].Comitato Etico Cantonale, Via Orico 5, 6501 Bellinzona, Switzerland [CE1872].Ethikkommission des Kantons St. Gallen, Kantonsspital\/Flurhof 7, Rorschacherstrasse 95, 9007\u2009St. Gallen, Switzerland [EKSG 10\/001].Kantonale Ethikkommission Z\u00fcrich KEK (Abteilung 4), Sonneggstrasse 12, 8091 Z\u00fcrich, Switzerland [KEK-ZH 2010\u2013023\/4].Kantonale Ethikkommission Aarau, Bachstrasse 15, 5001 Aarau, Switzerland [EK2010\/034].For further details, please refer to the main publications for the BASKET-PROVE () and the BASKET-PROVE II () trials.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"226"}}